Notice for International Patients & Caregivers
English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.
Oral Small-Molecule Agents Active Trials in China
As of 2026-09-04, there are 9 active clinical trials investigating Oral Small-Molecule Agents for multiple myeloma across 26 provinces and 102 study centers in China. Oral small-molecule agents span CELMoD degraders, BCL-2 inhibitors and HDAC inhibitors. Their oral route suits long-term administration, and they are typically combined with antibodies or immunomodulators to switch mechanism after resistance.
Active Studies (9)
Population synthesized by CMDNShowing 2 published English records of 9 registry trials.